A non-inferiority, phase III trial of gemcitabine plus capecitabine versus gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer
一项针对吉西他滨联合卡培他滨与吉西他滨联合卡铂作为晚期三阴性乳腺癌患者一线治疗和肿瘤浸润淋巴细胞作为预后生物标志物的非劣效性 III 期试验
期刊:Therapeutic Advances in Medical Oncology
影响因子:4.3
doi:10.1177/17588359241240304
Xiaodong Liu, Weipeng Zhao, Yongsheng Jia, Yehui Shi, Xu Wang, Shufen Li, Pin Zhang, Chen Wang, Chunfang Hao, Zhongsheng Tong